Concepta Diagnostics Turning Concepts into Conception and engaging a highly motivated customer base Penny McCormick Annual General Meeting 2 nd July 2020 Strictly Private and Confidential. Not to be copied.
Document information The information contained in this document and made verbally to you (together the “Presentation”) is confidential and is being supplied to persons with professional experience in matters relating to investments and/or to high net worth companies as described in Article 19(5) and 49(2) respectively of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI. 2001/No.1335) (as amended) made pursuant to section 21(5) of the Financial Services and Markets Act 2000 and, if permitted by applicable law, is being supplied outside the United Kingdom to professionals or institutions whose ordinary business involves them in investment activities. The information contained in this document is not intended to be viewed by, or distributed or passed on (directly or indirectly) to, any other class of persons. Accordingly, information contained in the Presentation is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published in whole or in part, for any purpose. In particular, the distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction. No representation or warranty, express or implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any such information or opinions by Concepta Plc (the “Company”) or any of its directors, members, officers, employees, agents or advisers. Notwithstanding this, nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently. The Presentation does not constitute any part of an offer of, or invitation to apply for, securities in the Company. Strictly Private and Confidential. Not to be copied.
Agenda Concepta Leadership Commercial Strategy Non-Exec Board R&D Vision, Mission, Purpose Operational leverage 2020 Commitments 2020 Delivery & Milestones Technology Forward Principles Our place in the market Future investment Market opportunity Summary Strictly Private and Confidential. Not to be copied.
New leadership team for growth Highly experienced Penny McCormick Lisa Link Maddy Kennedy Dr Karen Whiting consumer MedTech team CEO CFO CTO Product Specialist with leadership • Women’s health • • • Proven CFO for 20 years immunoassay 30 years consumer health commercial specialist transformational out- expertise BTB and OTC and beauty • 15 years in women’s • • licensing, acquisition Fertility specialisms: 12 years Unipath VP OTC; in women’s device health medical devices and IPO Unipath, male fertility Clearblue, Persona • plus IVD • 20 years life science and assay development Launch of first ever digital development and • FMCG marketing • tech specialties Multiple product launches pregnancy test • leadership • • Digital health & Programme leadership & Annualised category commercialisation • Operational & therapeutics portfolio, delivery spend to €10m regulatory ownership to • Alliance Pharma Medicine Management ISO 13485, IVDD software development • In/Out licensing: £32m Bayer deal Strictly Private and Confidential. Not to be copied.
Non-Exec Board Experts in commercialisation and Adam Reynolds Peter Dines Lyn Rees Neil Mesher Chairman Non-Exec Director Non-Exec Director Non-Exec Director investment of IVDs and consumer technology Chairman, investor and NED COO and Head of Lifesciences CEO Phillips UK & Eire. CEO of YourGene Health. portfolio including EKF, Mercia Asset Management Plc. Board member of the Former CEO and Association of British Yourgene Former MD positions in Directorships including Alere, Healthcare Industries (ABPI) medical device tech space The BBI Group Strictly Private and Confidential. Not to be copied.
Our vision for Concepta, Technology and Women Our Vision Our Mission Our Purpose Is a world where all women Is to help women and couples to start their Is to use our expertise and technology to improve self and couples have access to journey at home and make fact-based decisions care and support individuals and organisations with a information about their as early as possible, supporting their decision need for personalized diagnostics or monitoring. reproductive health, without making on next steps, where their body and Is to analyse data to demonstrate our own being misled. financial circumstances afford them the ability to effectiveness and learn more about women’s cycles so do so. that we can educate more effectively. Is for myLotus to be the go-to brand for trusted Is to be a highly ethical, trusted organisation that conception and fertility advice and tracking, and values its workforce and rewards talent; that provides up to date content regarding fertility. a safe and supporting working environment, whilst empowering its team to deliver for the good of its customer base. Strictly Private and Confidential. Not to be copied.
Our superior technology that proves itself The only fertility monitor that captures success rates with its own pregnancy testing regime: visible evidence Sophisticated OD analysis , converted to analyte concentration with 99% accuracy Quantitative LH testing throughout the cycle , with a pregnancy test at the end of the cycle 10 minutes to read a test, with monitor prompting tests: ease of use Option to test more than once a day – capturing LH surges regardless of whether they last hours or days Finding reliable ways to determine the moment of ovulation is a critical task in the control of human conception Strictly Private and Confidential. Not to be copied.
Making a difference Digital Fertility monitor Temperature ovulation tests + tests methods (Ava) myLotus ( Clearblue) (Clearblue) Works for ALL women Fertile window Yes Yes but with limitations Yes but with limitations No Real time testing Predictive Yes Retrospective Retrospective Retrospective Laboratory equivalence Commercially available Hormone profile Yes No No No OPKs have testing Each monthly cycle, presented App for easy UI Yes Some Yes Some thresholds ranging from 20 via the myLotus App, provides a to 50 mIU/ml. That’s a Controlled sample Yes No No N/A clear cycle map significant variation. So if one experiences a low LH Full cycle data Yes No Limited Yes Ovulation can be understood, surge one month, and the (low, high, peak) test isn’t very sensitive, and predicted Compare cycles Yes (12) Limited Yes (6) Yes results may show a woman that she didn’t ovulate — Irregular cycles Yes No No Yes when she actually did. PCOS Yes No No No LH surge, no ovulation Yes No No No Unique to you Yes No No No Month 1 cost £149.00 £37.00 £106.70 £349.00 Month 2+ cost £59.00 £37.00 £26.70 N/A Strictly Private and Confidential. Not to be copied.
Market opportunity in growth sector 1 MarketWatch. 2. NICE. 3. Alliende et al., Mean versus individual hormonal profiles in the menstrual cycle; Fertility and Sterility 2002 OPK = Ovulation predictor kits Strictly Private and Confidential. Not to be copied.
Market opportunity in growth sector Key Growth Drivers Declining fertility rates Highly accurate Delayed conception: Fertility Declining male overall rate of women 40+ technology coming to fertility: c.50% market surpassed that of women under 20 for the first time in 2016 (ONS). Average age of mothers at childbirth is 30.6 years 4 Increasing engagement with apps Improved success rates of Social acceptance for and tracking devices: greater IVF (2018 value: assisted conception support engagement with our own health $17.7bn 5 ). 70% of clinics and advice: social media and lifestyle privately funded driven 4. Statista 2020. 5. Grand View Research Strictly Private and Confidential. Not to be copied.
Attractive growth potential SPAIN ITALY FRANCE UK GERMANY TOTAL Based on actual UK retail data (IRI, April Population 46m 60m 65m 68m 84m 2019): • Estimate 1% of OPK volume in Europe OPK retail units 228k 296k 322k 336k 413k £6m • 5% of European OPK test volume is Clinic IUI Cycles 9.2k 11.9k 13k 13.5k 16.6k estimated c. £30m • Our aim is to secure this range percentage over 3yr period 5% of retail units share 11.4k 14.8k 16.1k 16.8k 20.65k 79.8k Revenue £4.1m £5.4m £5.9m £6.1m £7.5m £29m We have the potential to 5% of IUI share 0.5k 0.6k 0.7k 0.7k 0.8k 3.3k increase the addressable market value due to Revenue £182k £219k £256k £256k £292k £1.2m premium pricing, 5% Revenue Potential £4.3m £5.6m £6.2m £6.4m £7.8m £30.3m and drive value into the category OPK = Ovulation predictor kits IUI = Intrauterine Insemination Strictly Private and Confidential. Not to be copied.
Recommend
More recommend
